Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 291

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 291
---
,243 Lease liabilities8,887 8,801 Current portion of convertible senior notes, net201,776 8,641 Total current liabilities309,920 97,383 Convertible senior notes, net279,334 398,594 Long-term debt, net104,211 115,202 Lease liabilities44,645 54,806 Contingent consideration20,241 24,698 Other liabilities16,817 13,573 Total liabilities775,168 704,256 Commitments and contingencies (Note 19)Stockholders’ equity:  Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December 31, 2024 and 2023— — Common stock, par value $0.001; 250,000,000 shares authorized; 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024 and 46,481,174 shares issued and outstanding at December 31, 202347 46 Treasury stock, at cost, 837,240 and zero shares at December 31, 2024 and 2023, respectively, inclusive of excise tax(25,121)— Additional paid-in capital1,009,435 976,633 Accumulated deficit(206,356)(106,796)Accumulated other comprehensive income343 247 Total stockholders’ equity778,348 870,130 Total liabilities and stockholders’ equity$1,553,516 $1,574,386 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-5

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts) Year Ended December 31, 202420232022Revenues:   Net product sales$697,186 $672,245 $664,150 Royalty revenue3,780 2,733 2,673 Total revenues700,966 674,978 666,823 Operating expenses:   Cost of goods sold170,428 184,669 199,295 Research and development81,577 76,257 84,797 Selling, general